acute myeloid leukemia (AML). In the general population, the incidence rate of MDS is approximately 5 per 100,000 people per year. 1 , 2 MDS is rare among children/adolescents and young adults, with an incidence rate of 0.2 per 100,000 people per year
Search Results
Myelodysplastic Syndromes
Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O’Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. Thompson, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, and Maoko Naganuma
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation
Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt, and James K. Schwarz
the potential benefits of the use of several therapies to treat patients with FLT3 -ITD mutations Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an estimated incidence of 3 cases per 100,000 people. 1
Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria
Nirmala K. Manjappachar, John A. Cuenca, Claudia M. Ramírez, Mike Hernandez, Peyton Martin, Maria P. Reyes, Alba J. Heatter, Cristina Gutierrez, Nisha Rathi, Charles L. Sprung, Kristen J. Price, and Joseph L. Nates
stem cell transplant type, and (D) severe neutropenia status (absolute neutrophil count <500/mm 3 ). Differences between the curves were assessed using the log-rank test. Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia
Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis
Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans, and Cary P. Gross
schematic view of the Markov model is summarized in Figure 2 . Patients entered the model in the recurrence-free state and remained in that state until they developed congestive heart failure (CHF), distant recurrence (DR), or acute myeloid leukemia (AML
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
Jan Philipp Bewersdorf, Scott F. Huntington, and Amer M. Zeidan
Acute myeloid leukemia (AML) remains the most common form of acute leukemia in adults, with a 5-year survival rate of 30.5% among all patients diagnosed between 2012 and 2018 in the United States. 1 Due to a combination of advances in supportive
Clinical Trial Accrual at Initial Course of Therapy for Cancer and Its Impact on Survival
Nicholas G. Zaorsky, Ying Zhang, Vonn Walter, Leila T. Tchelebi, Vernon M. Chinchilli, and Niraj J. Gusani
the greatest absolute number of patients in trials: breast, non–small cell lung cancer (NSCLC), pancreas, acute myeloid leukemia, brain, prostate, melanoma, kidney, myeloma, and colorectal 2. Two facility levels: community and academic 3. Four age
The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features
Peter L. Greenberg
undergo evolution to or toward acute myeloid leukemia (AML). Pathogenetic mechanisms contributing to clinical phenotypes relate to critical molecular and biologic features. This article focuses on recently reported advances that describe major components
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis
Nathan J. Moore, Megan Othus, Anna B. Halpern, Nicholas P. Howard, Linyi Tang, Kyle E. Bastys, Mary-Elizabeth M. Percival, Paul C. Hendrie, Garrett A. Hartley, Verna L. Welch, Elihu H. Estey, and Roland B. Walter
Background Adults with acute myeloid leukemia (AML) or other high-grade myeloid neoplasms typically remain hospitalized during the several weeks of profound pancytopenia after intensive induction chemotherapy. However, the need for
Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia
Sandipkumar H. Patel, Sumithira Vasu, Ling Guo, Olivia Lemaster, John C. Byrd, and Alison Walker
intravenously on days 1–3) because of the presence of the IDH1 mutation, which is present in 7% to 14% of patients with acute myeloid leukemia (AML). 5 On day 8 of 7+3 treatment, she developed hemoptysis and blurry vision due to bilateral preretinal
Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
Kamya Sankar and Brady L. Stein
transformation to myelofibrosis (MF) or acute myeloid leukemia (AML). In 2005, the discovery of molecular abnormalities associated with PV and ET were instrumental in understanding the pathophysiologic and clinical manifestations of these disorders. 1 JAK2
